Our Partners
Internal Collaborators
Manisha Balwani, MD, MS
Genetics and Genomics
Emily J. Gallagher, MD
Endocrine, Diabetes and Bone Diseases
Bruce D. Gelb, MD
Pediatrics
Carol R. Horowitz, MD
Internal Medicine
Amy Kontorovich, MD
Cardiovascular Disease
Matthew A. Levin, MD
Anesthesiology
Ruth Loos, PhD
Environmental Medicine & Public Health
Aimee Lucas, MD
Gastroenterology
External Collaborators
Kathleen Carole Barnes
University of Colorado Denver - Anschutz Medical Campus
Toby Bloom
New York Genome Center
Esteban G. Burchard, MD, MPH
University of California, San Francisco
Carlos Bustamante
Stanford University
Christopher Gignoux
University of Colorado Denver - Anschutz Medical Campus
John M. Greally, Ph.D., M.B.,B.Ch.
Albert Einstein College of Medicine
Rasika Ann Mathias, Sc.D.
The Johns Hopkins University
Melissa P. Wasserstein, M.D.
Albert Einstein College of Medicine
Genevieve Wojcik
Stanford University
Noah Zaitlen, PhD
University of California, San Francisco
GenomicsFirst Committee
The GenomicsFirst Committee is a team of internal experts in genomic medicine at Mount Sinai. This committee was established to guide efforts in the development and use of genomic screening in clinical care across the Mount Sinai Health System.
Members
George Diaz, MD, PhD
Chief, Division of Medical Genetics, Department of Genetics and Genomic Sciences
Randi Zinberg, MS, CGC
Director, Master of Science Program in Genetic Counseling
Aimee Lucas, MD, MS
Associate Professor, Henry D. Janowitz Division of Gastroenterology, Department of Medicine
Amy Kontorovich, MD, PhD
Medical Director, Adult Cardiovascular Genetics, Zena and Michael A. Wiener Cardiovascular Institute
Internal Stakeholders
Charles Bronfman Institute for Personalized Medicine
The Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai is driving innovation in the data-driven and gene-based individualization of health care.
BioMe
Funded by The Charles Bronfman Institute for Personalized Medicine, BioMe is an electronic medical record-linked biobank that enables researchers to quickly and efficiently conduct genetic, epidemiologic, molecular, and genomic studies on large collections of research specimens linked with medical information.
Icahn Institute for Data Science and Genomic Technology
At the Icahn Institute, our vision is to transform biomedical research and healthcare delivery into a data-driven, evidence-based, patient-tailored discipline. Our research program focuses on harnessing huge molecular datasets to address complex diseases, using advanced biotechnologies to rapidly test novel treatments tailored to each patient, and bringing these treatments to benefit patients faster than has ever been possible.
Department of Medicine
The Department of Medicine is at the forefront of twenty-first century medicine with an uncompromising commitment to providing excellent patient care; to conducting cutting-edge research; and to the rigorous training of tomorrow’s physicians and physician-scientists.
INGH
We are building a new model for translational biomedical research enabled by new technologies and the changing landscape of healthcare.
Department of Genetics and Genomic Sciences
At the Department of Genetics and Genomic Sciences, our research and clinical teams work together to translate research insights to improve patient diagnostics and treatment.
We are committed to precision medicine, tailoring treatments to our patient’s specific needs. We’re able to achieve such personalized results by classifying patients into subpopulations based on their susceptibility to a particular disease or response to a particular treatment.
External Partners
Sema4
Sema4® is a patient-centered predictive health company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease.
New York Genome Center
The New York Genome Center (NYGC) is an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative diseases, neuropsychiatric diseases, and cancer, leveraging our strengths in whole genome sequencing, genomic analysis, and development of genomic tools.